Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tirbanibulin

FDA-approved product (ointment, topical), marketed as Klisyri.

Registered studies
20
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tirbanibulin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other chemotherapeutics
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

20registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tirbanibulin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tirbanibulin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

    NCT01397799 · start 2013-12

    Registered record
    Registry ID
    NCT01397799
    Conditions
    Acute Myelogenous Leukemia
    Interventions
    KX2-391
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myelogenous Leukemia
    InterventionKX2-391
    PhasePhase 1
    Registry statusCompleted

  • A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

    NCT01764087 · start 2012-12

    Registered record
    Registry ID
    NCT01764087
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific; Gastric Cancer; Breast Cancer
    Interventions
    KX2-391 and Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2016-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific; Gastric Cancer; Breast Cancer
    InterventionKX2-391 and Paclitaxel
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

    NCT01074138 · start 2010-02

    Registered record
    Registry ID
    NCT01074138
    Conditions
    Bone-Metastatic, Castration-Resistant Prostate Cancer
    Interventions
    KX2-391
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-10
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone-Metastatic, Castration-Resistant Prostate Cancer
    InterventionKX2-391
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of KX2-391 in Patients With Advanced Malignancies

    NCT00658970 · start 2007-11

    Registered record
    Registry ID
    NCT00658970
    Conditions
    Solid Tumors; Lymphoma
    Interventions
    KX2-391
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11
    Completion
    2011-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Lymphoma
    InterventionKX2-391
    PhasePhase 1
    Registry statusCompleted

  • KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

    NCT00646139 · start 2007-10

    Registered record
    Registry ID
    NCT00646139
    Conditions
    Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    Src kinase inhibitor KX2-391; immunoenzyme technique; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-03
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    InterventionSrc kinase inhibitor KX2-391; immunoenzyme technique; pharmacological study
    PhasePhase 1
    Registry statusCompleted